Acne Clinical Trial
Official title:
Evaluation of the Cutaneous and Ocular Tolerance of RV4857A Sunscreen Product and Its Efficacy Against the Recurrence of Lesions Post Sun Exposure in Subjects With Facial Acne
Verified date | December 2021 |
Source | Pierre Fabre Dermo Cosmetique |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of this study is firstly to assess the tolerance of the sunscreen RV4857A-CD2110 after 28 days and 57 days of at least a twice daily on the study areas, secondly to assess anti-imperfection efficacy after 28 days and 57 days of use and its efficacy against recurrence of acne lesions post-sun exposure.
Status | Completed |
Enrollment | 45 |
Est. completion date | November 9, 2020 |
Est. primary completion date | November 9, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Years to 40 Years |
Eligibility | Inclusion Criteria: 1. Related to the population: - Females and/or males (with at least 25% of male) - Age: adults from 18 to 40 years old and adolescent from 12 to 17 years old (33% to 50% of the total population) - Considered "healthy subject" by the Investigator - Being of Phototype I to IV - Subject with combination to oily skin - Subject who foresees sun exposure during the first 2 months of the study - Subjects must be registered with health social security or health social insurance (if required by national regulations) - Subject and/or parent(s)/legal representative(s) who have signed his/her/their written informed consent for his/her participation in the study (or his/her/their child participation in the study) and a photograph authorization - For woman of childbearing potential: committing herself to use effective contraceptive method since at least 3 months before the beginning of the study and committing to it throughout the study - Regular users of very high protection sunscreen products. 2. Related to the disease: - For adults and adolescents: subject with mild to moderate acne with a total of 10 to 40 acne lesions (at least 5 non-inflammatory lesions (open and closed comedones) and at least 3 to 10 inflammatory lesions (papules and pustules) maximum on the face, excluding the nose area), at the inclusion. - Subject prone to have recurrence of acne lesions in autumn (declarative) Exclusion Criteria: 1. Related to the population: - Having participated in another clinical trial within 4 weeks before the inclusion visit and for a longer period if required in the Investigator's opinion Taking part or planning to participate in another clinical trial during the study in the same or another investigation centre - Breastfeeding or pregnant or not willing to take necessary precautions to avoid pregnancy during the study and for at least 3 months before the inclusion visit (for the woman of childbearing potential) - Subject or parent(s)/legal representative(s) deprived of freedom by administrative or legal decision or under guardianship - Subject or parent(s)/legal representative(s) not able to be contacted in case of emergency - Subject admitted in a sanitary or social facility - Subject planning a hospitalization during the study 2. Related to the disease - Cutaneous pathology (psoriasis, atopic dermatitis, skin infectious disease of viral, bacterial, fungus or parasitic origin …) or dermatological condition (especially pityriasis versicolor, severe pigmentation disorders) on the studied zone other than acne liable to interfere with the data of the study - Severe acne - Clinical signs of hormonal disfunctions or hyperandrogenism - Excessive exposure to sunlight or UV-rays within the previous month - Having history of abnormal reactions from exposure to sunlight - Use of self tanning product during the previous month History of hypersensitivity or intolerance to any cosmetic product 3. Related to treatments - Use of a systemic or topical medication with anti-inflammatory or photosensitising products during the previous 2 weeks and for systemic medication with corticoids and/or antihistaminics during the previous 4 weeks - Use of a systemic treatment for acne during the previous month for antibiotics, zinc gluconate and hormonal treatment and during the 6 previous months for isotretinoin - Use of a topical treatment for acne during the previous month (benzoil peroxide, retinoid, antibiotics, azelaic acid…) - Use of anti-acneic or anti-seborrheic cosmestic care (containing alpha hydroxy-acids, retinoic derivatives..) during the 15 previous days - Use of other topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous tolerance and efficacy of the studied product (according to the investigator's appreciation) - Any surgery, chemical or physical treatment on the experimental area within the 12 months prior to the study or foreseeing it for the duration of the study - Woman whose oral contraception is instaured or changed for less than 3 months |
Country | Name | City | State |
---|---|---|---|
Portugal | PhD Trials® | Lisboa |
Lead Sponsor | Collaborator |
---|---|
Pierre Fabre Dermo Cosmetique |
Portugal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of the dermatological physical signs | The assessment of the dermatological physical signs is based on a visual examination | Change from Baseline to 30 minutes after product application, to 29 and 57 days later | |
Primary | Assessment of the dermatological functional signs | The functional signs is assessed by questioning the subject | Change from Baseline to 30 minutes after product application, to 29 and 57 days later | |
Primary | Assessment of the ophthalmological physical signs | The assessment of the ophthalmological physical signs is based on a dermatologist visual examination | Change from Baseline to 30 minutes after product application, to 29 and 57 days later | |
Primary | Assessment of the ophthalmological functional signs | The functional signs is assessed by questioning the subject | Change from Baseline to 30 minutes after product application, to 29 and 57 days later | |
Primary | Assessment of the Tear film Break Up Time (BUT) | The tear film break-up time is a test to measure the relative stability of the pre-corneal tear film. This examination is performed by the same Ophthalmologist thanks to a biomicroscope after blinking (using a chronometer). The measured time will be expressed in seconds | Change from Baseline to 30 minutes after product application, to 29 and 57 days later | |
Primary | Assessment of global tolerance assessment (dermatogical assesment), a 5-point scale | Excellent: no functional nor physical signs related to the investigational product observed or reported by the subjects
Very good Good Moderate Bad |
Change from Baseline to 29 and 57 days later | |
Primary | Assessment of global tolerance assessment (ophthalmological assessment), a 5-point scale | Excellent: no functional nor physical signs related to the investigational product observed or reported by the subjects
Very good Good Moderate Bad |
Change from Baseline to 29 days later | |
Secondary | Change of the number of total acne lesions on the face | by counting according to the method of Lucky | Change from Baseline to 29, 57 and 85 days later | |
Secondary | Change of the number of non-inflammatory lesions (open and closed comedones) on the face | by counting according to the method of Lucky | Change from Baseline to 29, 57 and 85 days later | |
Secondary | Change of the number of inflammatory lesions (papules, pustules, nodules) on the face | by counting according to the method of Lucky | Change from Baseline to 29, 57 and 85 days later | |
Secondary | Assessment of the non-comedogenic potential | by statistical comparison of open and closed comedones counted by the investigator on the face before and after 28 days of application of investigational product | Change from Baseline to 29 days later | |
Secondary | Change of the acne severity, assess by Global Acne Evaluation (GEA) on a 6-point scale | 0: Clear
1: Almost clear 2: Mild 3: Moderate 4: Severe 5 : Very Severe |
Change from Baseline to 29, 57 and 85 days later | |
Secondary | Evaluation of the global acne evolution on a 6-point scale | -1: Worsening, 0: No change,
Mild improvement, Moderate improvement, Good improvement, Very good improvement |
Change from Baseline to 29 and 57 days later | |
Secondary | Evaluation of the global product efficacy by the subjects themselves regarding rebound effect in Autumn | Questions Q24 and Q25 at D85 in the self-questionnaire | Change from Baseline to 85 days later | |
Secondary | Assessment of the cosmetic acceptability and perceived efficacy of the product | The self subject assemsment consists of different questions concerning participants' perception of the product's efficacy (majority of scales ranging from 0 to 10 where 0 was the worst satisfaction and 10 the best one) | Change from Baseline to 29 and 57 days later | |
Secondary | To evaluate the impact on Quality of Life of subjects through questionnaires | Quality of Life questionnaires consist of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week | Change from Baseline to 29 and 57 days later |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05097157 -
Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions
|
N/A | |
Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT04806594 -
Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar.
|
N/A | |
Recruiting |
NCT03465150 -
Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital
|
||
Completed |
NCT02250859 -
A Pharmacokinetic Study of Minocycline in Male and Female Volunteers
|
Phase 1 | |
Completed |
NCT01206348 -
Combination Treatment for Moderate to Severe Acne
|
Phase 4 | |
Terminated |
NCT01193764 -
Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris
|
N/A | |
Completed |
NCT00725439 -
An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne
|
Phase 2 | |
Completed |
NCT05640388 -
Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
|
||
Completed |
NCT04873089 -
Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin
|
||
Recruiting |
NCT05941065 -
Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin
|
N/A | |
Recruiting |
NCT06120452 -
A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation
|
N/A | |
Completed |
NCT04300010 -
Blue Light Therapy of C. Acnes
|
Phase 4 | |
Recruiting |
NCT06202274 -
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
|
N/A | |
Completed |
NCT04559022 -
Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring
|
N/A | |
Terminated |
NCT02431494 -
Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris
|
N/A | |
Completed |
NCT05469880 -
Efficacy and Tolerance of Formula 609613 37 in Acneic Patients
|
N/A | |
Completed |
NCT02944461 -
Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris
|
Phase 4 | |
Completed |
NCT01951417 -
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
|
Phase 4 | |
Completed |
NCT01701024 -
Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne
|
Phase 3 |